Background Genome-wide association studies (GWAS) in Parkinson's disease have increased
the scope of biological knowledge about the disease over the past decade. We aimed to …

With recent findings connecting the Epstein-Barr virus to an increased risk of multiple sclerosis
and growing concerns regarding the neurological impact of the coronavirus pandemic, …

Background Increasing evidence supports an extensive and complex genetic contribution to
PD. Previous genome‐wide association studies (GWAS) have shed light on the genetic …

Background There are currently no treatments that stop or slow the progression of Parkinson's
disease (PD). Case–control genome‐wide association studies have identified variants …

Parkinson’s disease is a genetically complex disorder. Multiple genes have been shown to
contribute to the risk of Parkinson’s disease, and currently 90 independent risk variants have …

Objective To determine if any association between previously identified alleles that confer
risk for Parkinson disease and variables measuring disease progression. Methods We …

Background Parkinson's disease (PD) is a neurodegenerative disease with an often
complex component identifiable by genome‐wide association studies. The most recent large‐scale …

Background Several reports have identified different patterns of Parkinson's disease
progression in individuals carrying missense variants in GBA or LRRK2 genes. The overall …

Personalized medicine promises individualized disease prediction and treatment. The
convergence of machine learning (ML) and available multimodal data is key moving forward. We …

Background An understanding of the genetic mechanisms underlying diseases in ancestrally
diverse populations is an important step towards development of targeted treatments. …